Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Al-Janabi A, et al. Among authors: yiu zzn. JAMA Dermatol. 2024 Jan 1;160(1):71-79. doi: 10.1001/jamadermatol.2023.4846. JAMA Dermatol. 2024. PMID: 38055239 Free PMC article.
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. J Invest Dermatol. 2018 Mar;138(3):534-541. doi: 10.1016/j.jid.2017.10.005. Epub 2017 Oct 17. J Invest Dermatol. 2018. PMID: 29054603 Free PMC article.
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. Br J Dermatol. 2019 Feb;180(2):329-337. doi: 10.1111/bjd.17036. Epub 2018 Oct 21. Br J Dermatol. 2019. PMID: 30070708 Free PMC article.
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. JAMA Dermatol. 2021 Jan 1;157(1):66-73. doi: 10.1001/jamadermatol.2020.4202. JAMA Dermatol. 2021. PMID: 33263718 Free PMC article.
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group. Alabas OA, et al. Among authors: yiu zzn. Br J Dermatol. 2023 Apr 20;188(5):618-627. doi: 10.1093/bjd/ljad004. Br J Dermatol. 2023. PMID: 36763783
93 results